title: [Clinical effect of combination chemotherapy with peplomycin and mitomycin C (PM therapy) in recurrent uterine cervical cancer].
abstract: Seventeen patients with recurrent uterine cervical cancer were treated with combination chemotherapy consisting of consecutive intravenous drip infusion of PEP 5 mg for 6 days and intravenous infusion of MMC 10 mg on the 6th day. Of twelve evaluable cases, 2 complete responses and 6 partial responses were obtained and the response rate was 67%. The median survival for responders was 61.3 weeks as compared with 28.0 weeks for non-responders. The initial clinical effect appeared after at least two courses. Pulmonary toxicity in the form of interstitial pneumonitis occurred in 8 cases (50%) including 2 cases of pulmonary fibrosis. This result suggests that PM therapy is a very useful treatment method for recurrent uterine cervical cancer which can be performed safely.
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D017663:Peplomycin; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000401:mortality
chemical_list: D008937:Mitomycins; D001761:Bleomycin; D016685:Mitomycin; D017663:Peplomycin